Skip to main content
Erschienen in: Clinical Rheumatology 10/2008

01.10.2008 | Case Report

Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up

verfasst von: Rezan Topaloğlu, Nuray Aktay Ayaz, Hans R. Waterham, Aysel Yüce, Fatma Gumruk, Özden Sanal

Erschienen in: Clinical Rheumatology | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) is an autoinflammatory syndrome. It is caused by the mutations of the mevalonate kinase gene. There is no consensus for specific therapy of HIDS, but there are some case reports and studies in regards to its treatment with drugs like colchicine, steroids, nonsteroid anti-inflammatory drugs, simvastatin, anakinra, thalidomide, and etanercept. We are reporting a case evaluated for the complaints of abdominal pain and febrile episodes with massive hepatomegaly, not common finding on physical examination, its treatment with etanercept, and long-term follow-up.
Literatur
1.
Zurück zum Zitat Drenth JP, Cuisset L, Grateau G et al (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 22:178–181PubMedCrossRef Drenth JP, Cuisset L, Grateau G et al (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 22:178–181PubMedCrossRef
2.
Zurück zum Zitat Drenth JP, Denecker NE, Prieur AM et al (1995) Hyperimmunoglobulin D syndrome. Presse Med 24:1211–1213PubMed Drenth JP, Denecker NE, Prieur AM et al (1995) Hyperimmunoglobulin D syndrome. Presse Med 24:1211–1213PubMed
3.
Zurück zum Zitat Drenth JP, Haagsma CJ, van der Meer JM (1994) Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 73:133–144 Drenth JP, Haagsma CJ, van der Meer JM (1994) Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 73:133–144
4.
Zurück zum Zitat de Dios Garcia D, varez-Blanco MJ (2001) Glucocorticoids but not NSAID abort attacks in hyper-IgD and periodic fever syndrome. J Rheumatol 28:925–926 de Dios Garcia D, varez-Blanco MJ (2001) Glucocorticoids but not NSAID abort attacks in hyper-IgD and periodic fever syndrome. J Rheumatol 28:925–926
5.
Zurück zum Zitat Simon A, Drewe E, van der Meer JW et al (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 75:476–483PubMedCrossRef Simon A, Drewe E, van der Meer JW et al (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 75:476–483PubMedCrossRef
6.
Zurück zum Zitat Drenth JP, Vonk AG, Simon A et al (2001) Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther 298(3):1221–1226PubMed Drenth JP, Vonk AG, Simon A et al (2001) Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther 298(3):1221–1226PubMed
7.
Zurück zum Zitat Bodar EJ, van der Hilst JC, Drenth JP et al (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63(7):260–264PubMed Bodar EJ, van der Hilst JC, Drenth JP et al (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63(7):260–264PubMed
8.
Zurück zum Zitat Drenth JP, van Deuren M, van der Ven-Jongekrijg J et al (1995) Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 85(12):3586–3593PubMed Drenth JP, van Deuren M, van der Ven-Jongekrijg J et al (1995) Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 85(12):3586–3593PubMed
9.
Zurück zum Zitat Arkwright PD, McDermott MF, Houten SM et al (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130(3):484–488PubMedCrossRef Arkwright PD, McDermott MF, Houten SM et al (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130(3):484–488PubMedCrossRef
10.
Zurück zum Zitat Demirkaya E, Çağlar MK, Waterham HR et al (2007) A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 26:1757–1759PubMedCrossRef Demirkaya E, Çağlar MK, Waterham HR et al (2007) A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 26:1757–1759PubMedCrossRef
11.
Zurück zum Zitat Topaloğlu R, Saatçi Ü (1991) Hyperimmunoglobulinemia D and periodic fever mimicking familial Mediterranean fever in the Mediterranean. Postgrad Med J 67(787):490–491PubMedCrossRef Topaloğlu R, Saatçi Ü (1991) Hyperimmunoglobulinemia D and periodic fever mimicking familial Mediterranean fever in the Mediterranean. Postgrad Med J 67(787):490–491PubMedCrossRef
12.
Zurück zum Zitat Çoban E, Terzioğlu E (2004) A patient with hyper-IgD syndrome in Antalya, Turkey. Clin Rheumatol 23:177–178PubMedCrossRef Çoban E, Terzioğlu E (2004) A patient with hyper-IgD syndrome in Antalya, Turkey. Clin Rheumatol 23:177–178PubMedCrossRef
13.
Zurück zum Zitat Mandey SHL, Schneiders MS, Koster J et al (2006) Mutational spectrum and genotype phenotype correlations in mevalonate kinase deficiency. Hum Mutat 27(8):796–802PubMedCrossRef Mandey SHL, Schneiders MS, Koster J et al (2006) Mutational spectrum and genotype phenotype correlations in mevalonate kinase deficiency. Hum Mutat 27(8):796–802PubMedCrossRef
14.
Zurück zum Zitat Rabinovich E, Livneh A, Langevitz P et al (2005) Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis 64(7):1009–1014PubMedCrossRef Rabinovich E, Livneh A, Langevitz P et al (2005) Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis 64(7):1009–1014PubMedCrossRef
15.
Zurück zum Zitat Hinson DD, Rogers ZR, Hoffmann GF et al (1998) Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Am J Med Genet 88:408–412CrossRef Hinson DD, Rogers ZR, Hoffmann GF et al (1998) Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Am J Med Genet 88:408–412CrossRef
Metadaten
Titel
Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up
verfasst von
Rezan Topaloğlu
Nuray Aktay Ayaz
Hans R. Waterham
Aysel Yüce
Fatma Gumruk
Özden Sanal
Publikationsdatum
01.10.2008
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 10/2008
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0911-3

Weitere Artikel der Ausgabe 10/2008

Clinical Rheumatology 10/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Nierenultraschall: Tipps vom Profi

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.